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BACKGROUND The treatment of coronary artery disease involving
distal segments remains a challenge. Differently from metallic plat-
form stents (MPS), bioresorbable vascular scaffolds (BVS) may
potentially provide expansive remodeling, the return of vessel vaso-
motion and permit surgical revascularization. Notwithstanding, data
at late follow-up in this setting are scant.
METHODS The Italian RAI Registry is an ongoing, spontaneous,
multicenter prospective data collection which evaluates all patients
treated at participating centres with the second-generation ever-
olimus-eluting Absorb BVS. Our analysis was restricted to patients
who received Absorb BVS implantation in at least one distal segment
of an epicardial coronary artery.
RESULTS Between March 2012 and June 2015, 1089 consecutive un-
selected patients were treated by BVS. 121 patients (mean age 59
years, 86% males) were included in this analysis. A total of 135 lesions
involving distal segments were treated with Absorb BVS in this cohort.
Seventy-six (63%) patients had an acute coronary syndrome. Diabetic
patients were 29 (24%). Multivessel coronary artery disease was pre-
sent in 69% of patients, and the median SYNTAX score was 17  12.
Multivessel implantation occured in 40 (33%) patients and 21% of
patients received metallic stents proximally. The total number of BVS
implanted was 269, with an average of 2.2/patient. Final scaffold
length was 28 mm in the majority of patients (52%) with 79 overlaps.
Procedural success occurred in 96% of patients. At a median follow up
of 25 months (interquartile range, 12 – 37 months), target lesion failure
rate was 5.8%. More in detail, adverse events were: 1 cardiac death, 5
target vessel myocardial infarctions, 4 target lesion revascularizations
because of deﬁnite scaffold thrombosis (3 sub-acute, 1 very late).
CONCLUSIONS By the data of the RAI registry, the implantation of
Absorb BVS in distal segments is promising. Randomized studies are
needed to assess the potential beneﬁt of BVS to treat distal coronary
lesions compared to MPS or incomplete revascularization.
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BACKGROUND Percutaneous coronary intervention (PCI) with bio-
resorbable vascular scaffold (BVS) placement holds great potential,
but concern has recently been raised regarding the risk of scaffold
thrombosis (ST). The aim of this study was to determine the risk of ST
following PCI with placement of an ABSORB BVS by conducting a
systematic review and meta-analysis.
METHODS Medline/PubMed, Cochrane CENTRAL, and meeting ab-
stracts were searched for all studies that included outcomes data in
patient following PCI with BVS placement. For studies comparing BVS
with drug-eluting stents (DES), pooled estimates of outcomes, pre-
sented as odds ratios (OR) [95% conﬁdence intervals], were generated
with random-effect models.
RESULTS Our analysis included 10,021 patients (8,303 with BVS and
1,718 with DES) with a follow-up of 6.45.1 months, age of 6011, 78%were male, 38% had stable angina, and 56% had ACS. CV death
occurred in 0.6% of patients with BVS, MI in 2.1%, target lesion
revascularization in 2.0%, and deﬁnite/probable ST in 1.2% of pa-
tients. Among BVS patients, 0.3% had acute ST and 0.6% had subacute
ST, yielding a risk of 0.9% for ST in the ﬁrst month. Meta-analysis
demonstrated patients that received BVS were at a higher risk of MI
(OR 2.06[1.26-3.36], p¼0.004) and deﬁnite/probable ST (OR 2.14 [1.02-
4.50], p<0.05) during follow-up (Figure).
CONCLUSIONS Patients undergoing PCI with BVS had increased
deﬁnite/probable ST and MI during follow-up compared with DES.
Measures to minimize scaffold thrombosis are warranted. Further
randomized controlled trials with the long-term follow-up will
determine the overall utility of BVS compared to DES implantation in
high-risk patient subgroups.
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BACKGROUND There is limited data on the impact of postdilation
(PD) on acute procedural and clinical outcomes in patients with long
and complex lesions treated with bioresorbable vascular scaffolds. We
sought to evaluate the effect of PD on procedural and clinical out-
comes in a ‘real world’ population.
METHODS We performed an analysis of patients who underwent BRS
implantation and enrolled into our institutional BVS STEMI FIRST and
EXPAND registries. Pre and post dilation were encouraged with at
least 1:1 preballoon: artery (B: A) and postballoon: scaffold (B: S) ratios
respectively. Baseline clinical and angiographic (including quantita-
tive coronary angiographic analysis; QCA) characteristics were
collected. The effect of PD on angiographic outcome were also eval-
uated using appropriate views taken immediately after BRS implan-
tation (before postdilation) and ﬁnal procedure when available.
Patients were followed up routinely through telephone call and hos-
pital visits. Procedural end points studied included device and pro-
cedure success and complication rates. Major adverse cardiovascular
events (MACE) studied included all-cause mortality, myocardial
infarct, target lesion revascularization and scaffold thrombosis.
RESULTS 294 patients with 387 lesions treated with 529 BRS were
studied of which 164 patients with 211 lesions underwent PD (Post B:S:
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B2211.06  0.12; mean postdilation balloon diameter 3.26  0.44mm; mean
maximal postdilation pressure: 16.05  4.24mmhg). Baseline clinical
characteristics were similar between the PD and non-PD groups. The
left anterior descending artery (47.8%) was the most commonly
treated vessel in the study population. Lesion complexity and calci-
ﬁcation were higher in the PD group (AHA B2/C lesion: 48.4% in PD vs
24.5% in non-PD, p < 0.001; Moderate/heavy calciﬁcation: 51.2% vs
29.6%, p<0.001). Treatment length was signiﬁcantly longer in PD
compared to non-PD (25.31 14.53 vs 20.06 10.13, p<0.001). Lesion
preparation (percentage predilation performed and pre B:A ratio) was
similar between the PD and non-PD groups. Acute lumen gain was
signiﬁcantly decreased in PD compared to non-PD (1.33 0.59 vs 1.53
0.63mm, p¼ 0.002). From QCA, PD resulted in a signiﬁcant increase
in reference vessel diameter (RVD, 0.16  0.37, p< 0.001), minimal
lumen diameter (MLD: 0.14  0.32mm, p < 0.001) and non-signiﬁcant
decrease in diameter stenosis [%DS: (-)0.03  12.39%, p¼ 0.976] after
BRS implantation. Overall device success rates was 99.5% and all-
cause mortality occurred in 2.7% of the study population with no
differences between the PD and non-PD groups. Other clinical out-
comes are currently being adjudicated and would be available on
presentation.
CONCLUSIONS In our study, while PD resulted in a marginal increase
in RVD and MLD after BRS implantation, acute lumen gain was smaller
in the PD group and short term procedural outcome and mortality
remained similar between the 2 groups.
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BACKGROUND No reports have described the ultrastructural changes
that occur over the course of bioresorption of the everolimus-eluting
Absorb BVS (150 mm PLLA-strut thickness with 6 mm PDLLA-coating)
[Abbott Vascular, Santa Clara, CA].
METHODS Eighteen Absorb BVS were implanted in main coronary
arteries of healthy Yucatan mini Swine. Transmission electron mi-
croscopy was performed at seven time points from 28-days to 48-
months. Ultrastructural changes of polymeric struts / resorption sites
(RS, > 36 months) were morphologically characterized.
RESULTS Up to 12-months, struts were intact with surrounding
macrophages and ﬁbroblasts. The PDLLA polymer coating was
observed as a black line of calciﬁed material (A) as thinly separated
from the strut polymer. Collagen deposition was seen along the sur-
faces with acellular cytoplasmic processes extending into the strut
surface from the surrounding cellular area (B & C). At 24-months the
acellular processes extended deeper into the strut surface. Collagen
and smooth muscle cells bordered the strut. At 30-months, some strut
surfaces remained intact with surrounding dense collagen and ﬁbro-
blasts (B) while other areas shows superﬁcial polymer micro-
fragmentation (A & C). Internally, struts appeared sparsely granular.
At 36-months RS were tightly surrounded by ﬁbrous tissue (B).
Cellular and collagen-proteoglycan ingrowth subdivided RS, which
show more dense granularity than at 30 months (A & C). At 42- and 48-
months, RS were reduced to multiple amorphous, densely granular
particles subdivided and surrounded by collagen and proteoglycan
rich matrix with myoﬁbroblasts and interspersed calciﬁed material.CONCLUSIONS Our investigation reveals the nature of the changes
seen within the polymeric struts. As polymer resorbs (30 - 36 months)
it shows increasing granularity (nonﬁbrellar glycoprotein) with
eventual replacement by a proteinceous matrix with integrated
collagen and myoﬁbroblasts at 48-months.
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BACKGROUND The data concerning the use of bioresorbable vascular
scaffolds (BVS) in coronary bifurcation lesions are limited. Given the
complexity of the procedure and the potential risk of struts’ damage it
is imperative to evaluate the efﬁcacy and long-term safety of BVS in
such lesions. The aim of the study was to evaluate the early and long-
term clinical outcomes of bifurcation stenting with BVS.
METHODS The study is a prospective, nonrandomized clinical registry
of patients with coronary bifurcation lesion treated with everolimus-
eluting BVS. Sixty consecutive patients, with stable coronary artery
disease or acute coronary syndromes were enrolled. The study
excluded patients with concomitant serious illnesses, those who were
unable to receive prolonged dual antiplatelet therapy or required
chronic oral anticoagulation therapy. Bifurcation lesion was deﬁned
and classiﬁed according to European Bifurcation Club deﬁnition and
Medina classiﬁcation. The main clinical study end point was a device-
oriented target lesion failure (TLF), deﬁned as the combination of
cardiac death, target vessel myocardial infarction, or clinically driven
target lesion revascularization.
RESULTS Sixty consecutive patients (male 71.7%, mean age 62.611.2
years) were included, 18 of them had diabetes mellitus (30%) and 10
chronic kidney disease (17%). True bifurcation lesion was found in 27
patients (45%). Nine lesions (15%) comprised the left main coronary
artery. On QCA the mean proximal and distal main vessel reference
diameters were 3.12  0.36 mm and 2.65  0.43 mm respectively,
whereas the mean lesion length and diameter stenosis were 12.73 
9.53 mm and 69.72  27.33 mm. The mean side branch (SB) reference
diameter was 2.34  0.36 mm, SB lesion length 5.66  5.27 mm, and
lesion diameter stenosis 44.58 27.47%. A total of 71 BVS were
implanted. Provisional T stenting was performed in 42 patients (70%),
distal main vessel stenting in one patient, systematic T stenting in 6
(10%), and T with minimal protrusion (TAP) in 2 patients (2.2%). SB
ostial stenting was performed in additional 9 patients (15%). The ﬁnal
